| Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine AAV Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hassson L, Hua T ... Lancet 363, 2022-31, 2004 | 4126* | 2004 |
| The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure TDI Group New England Journal of Medicine 336, 525-533, 1997 | 3515 | 1997 |
| Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients VEJATI Jamerson K, Weber MA, Bakris GL, Bahlof B, Pitt B, Shi V, Hester A ... New England J Medicine 359, 2417-28, 2008 | 3445 | 2008 |
| 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American … GN Levine, ER Bates, JA Bittl, RG Brindis, SD Fihn, LA Fleisher, ... Circulation 134 (10), e123-e155, 2016 | 3020 | 2016 |
| 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology … SD Fihn, JM Gardin, J Abrams, K Berra, JC Blankenship, AP Dallas, ... Journal of the American College of Cardiology 60 (24), e44-e164, 2012 | 2854 | 2012 |
| Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial EJ Ziegler, CJ Fisher Jr, CL Sprung, RC Straube, JC Sadoff, GE Foulke, ... New England Journal of Medicine 324 (7), 429-436, 1991 | 1883 | 1991 |
| Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction SI Waldo AL, Camm AJ, DeRuyer H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B ... Lancet 348, 7-12, 1996 | 1720 | 1996 |
| Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors M Packer, M Gheorghiade, JB Young, PJ Costantini, KF Adams, RJ Cody, ... New England Journal of Medicine 329 (1), 1-7, 1993 | 1165 | 1993 |
| Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial ARJ Black HR, Elliott WJ, Granits G, Grambsch P, Lucente T, White WB, Neaton ... JAMA 289, 2073-82, 2003 | 998 | 2003 |
| Effect of valsartan on the incidence of diabetes and cardiovascular events NS Group New England Journal of Medicine 362 (16), 1477-90, 2010 | 951 | 2010 |
| Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary … WMAATI Bakris GL, Sarafiis PA, Weir MR, Dahlof B, Pitt B, Hamerson K ... Lancet 375 (9721), 1173-81, 2010 | 732 | 2010 |
| Effect of nateglinide on the incidence of diabetes and cardiovascular events NS Group New England Journal Medicine 362 (16), 1463-76, 2010 | 591 | 2010 |
| Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure AOHFTAI McMurray JJ, Pitt B, Latini R, Maggioni AP,Solomon SD, Keefe DL ... Circ Heart Failure 1 (1), 17-24, 2008 | 521 | 2008 |
| Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) WTJMI Cohn JN, Pfeffer MAQ, Rouleau J, Sharpe N, Swedberg K, Struab M, Wiltse C Eur J Heart Failure 5 (5), 659-667, 2003 | 449 | 2003 |
| Circulating concentrations of proinflammatory cytolcines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy MA Munger, B Johnson, IJ Amber, KS Callahan, EM Gilbert The American journal of cardiology 77 (9), 723-727, 1996 | 388 | 1996 |
| Medication nonadherence: an unrecognized cardiovascular risk factor MA Munger, BW Van Tassell, J LaFleur Medscape general medicine 9 (3), 58, 2007 | 386 | 2007 |
| Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure R Hirschberg, J Kopple, P Lipsett, E Benjamin, J Minei, T Albertson, ... Kidney international 55 (6), 2423-2432, 1999 | 364 | 1999 |
| In vivo human time-exposure study of orally dosed commercial silver nanoparticles MA Munger, P Radwanski, GC Hadlock, G Stoddard, A Shaaban, ... Nanomedicine: Nanotechnology, Biology and Medicine 10 (1), 1-9, 2014 | 237 | 2014 |
| Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure et al. Packer, Milton, Carver Joseph R, Rodeheffer Richard N Engl J Med 325 (21), 1468-75, 1991 | 207* | 1991 |
| Exceptional early blood pressure control rates: the Accomplish trial AI Jamerson K, Bakris GL, Dahlof B Blood Pressure 16, 80-86, 2007 | 187 | 2007 |
Michael A. WeberProfessor of Medicine, SUNY Downstate College of MedicineEmail verificata su cs.com